December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Diffuse Lamellar Keratitis: Can Fluoroquinolones Be A Cause?
Author Affiliations & Notes
  • FS Mah
    Ophthalmology Charles T Campbell Laboratory University of Pittsburgh Pittsburgh PA
  • DK Dhaliwal
    Ophthalmology University of Pittsburgh Pittsburgh PA
  • EG Romanowski
    Ophthalmology Charles T Campbell Laboratory University of Pittsburgh Pittsburgh PA
  • KA Yates
    Ophthalmology Charles T Campbell Laboratory University of Pittsburgh Pittsburgh PA
  • YJ Gordon
    Ophthalmology Charles T Campbell Laboratory University of Pittsburgh Pittsburgh PA
  • Footnotes
    Commercial Relationships    F.S. Mah, Allergan Corp F; D.K. Dhaliwal, None; E.G. Romanowski, None; K.A. Yates, None; Y.J. Gordon, None. Grant Identification: Support: Allergan Corp, and RPB
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2097. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      FS Mah, DK Dhaliwal, EG Romanowski, KA Yates, YJ Gordon; Diffuse Lamellar Keratitis: Can Fluoroquinolones Be A Cause? . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2097.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Diffuse lamellar keratitis (DLK) is an enigmatic inflammatory response that has been seen following LASIK. There have been many theories regarding its etiology. To date, commercially-available topical fluoroquinolones have not been implicated as a potential cause of DLK. In this study, we examined whether fluorquinolones placed under the LASIK flap will induce DLK in the NZW rabbit LASIK model. Methods: One-half cross-section LASIK flaps were created using a Moria C-B automated microkeratome in both eyes of 20 New Zealand white rabbits. The rabbits were divided into 4 treatment groups: I) 0.3% ciprofloxacin (Ciloxan®, Alcon Laboratories, Inc.); II) 0.3% ofloxacin (Ocuflox®, Allergan, Inc.); III) BSS® (Alcon Laboratories, Inc.); and IV) Pseudomonas aeruginosa endotoxin (Sigma Chemical Co.). Treatment included instillation of one drop under the flap and topical applicaton QID the following day. Following treatment, eyes were examined via slit lamp and graded (Linebarger grading scale) in a masked fashion on post-operative day 1. Results: (See Table) *Monte Carlo Two-tailed p = 0.0693; **Kruskal-Wallis ANOVA p=0.0694 Conclusion: Although DLK was observed in eyes of all groups, there were no statistical differences among the groups in this preliminary study. Additional trials will be performed to increase the number of eyes per group to answer this important question. Support: Allergan Corp, and RPB. Results  

Keywords: 545 refractive surgery: complications • 548 refractive surgery: LASIK • 437 inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×